Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]

Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]